Who Paid My Doc
Jordon Jaggers
Allergy North Olmsted, OH Medical Doctor
NPI 1174159198 CMS profile 11632513
24700 Lorain Rd Ste 207, North Olmsted, OH 44070
General payments
$26
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jordon Jaggers of North Olmsted, OH is reported in the CMS Open Payments database as having received $26 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 3rd percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $26 | 1 |
Beside peers
- Jordon Jaggers
- Allergy median
- Middle half of Allergy
- National median
In program year 2025, general payments to Jordon Jaggers were reported at $26. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.
Show as a table
| Year | Jordon Jaggers | Allergy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $506 | $151–$1,337 | $163 |
| 2020 | $0 | $409 | $108–$1,162 | $114 |
| 2021 | $0 | $549 | $125–$1,485 | $132 |
| 2022 | $0 | $666 | $161–$1,594 | $149 |
| 2023 | $0 | $780 | $186–$1,916 | $160 |
| 2024 | $0 | $1,031 | $271–$2,196 | $164 |
| 2025 | $26 | $1,143 | $226–$2,504 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
128
Drug cost
$42,293
Branded share of claims
59.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 33 | $24,895 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 11 | $8,232 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 16 | $5,323 | |
| Epinephrine | Generic | 11 | $2,325 | |
| Azithromycin | Generic | 16 | $608 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 16 | $522 | |
| Fluticasone Propionate | Generic | 25 | $387 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy in Ohio
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.